Key result
LVAD implantation in patients with end-stage heart failure did not reduce 6-month mortality (26% vs 23.3%) but significantly reduced rehospitalizations and improved quality of life.
Why the study?
To evaluate mortality, postoperative complications, clinical course, and quality of life within 6 months following LVAD implantation in patients with heart failure.
Does centrifugal-flow left ventricular assist device implantation improve clinical outcomes and quality of life in patients with end-stage heart failure with reduced ejection fraction?
Population
53 patients who met criteria for LVAD implantation
Comparison
LVAD implantation vs refusal of implantation
Design
Cohort study
Follow-up
6 months
Authors
Loading...
Observational LVAD data in advanced HF are hypothesis-generating; leaves open whether implantation improves 6-month survival or quality of life.
Cohort (n=53)
Does centrifugal-flow left ventricular assist device implantation improve clinical outcomes and quality of life in patients with end-stage heart failure with reduced ejection fraction?
Absolute Event Rate: 26% vs 23.3%
In patients with end-stage HFrEF, LVAD implantation improves quality of life, functional class, and reduces rehospitalizations at 6 months, but is associated with significant postoperative complications and no short-term mortality benefit compared to medical therapy.
Shahramanova et al. (2024) conducted a cohort in end-stage heart failure with reduced ejection fraction (n=53). Centrifugal-flow left ventricular assist device (LVAD) implantation vs. Refusal of LVAD implantation was evaluated on Mortality. LVAD implantation in patients with end-stage heart failure did not reduce 6-month mortality (26% vs 23.3%) but significantly reduced rehospitalizations and improved quality of life.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: